IP Verse

Sandoz competitive analysis

Loading summary...

Latest oppositions filed by Sandoz

Explore patent oppositions filed by Sandoz against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3539540
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 18, 2025
EP3490560
Methods Of Treating Prostate CancerJANSSEN PHARMACEUTICASep 17, 2025
EP3321270
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 3, 2025
EP4176877
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry DiseaseAMICUS THERAPEUTICSSep 3, 2025
EP3914247
Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry DiseaseAMICUS THERAPEUTICSAug 13, 2025
EP3518932
Treatment Of Prostate CancerMYOVANT SCIENCESAug 7, 2025
EP3242666
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSJul 15, 2025
EP4125903
Methods For Dose Initiation Of Aripiprazole TreatmentsOTSUKA PHARMACEUTICALJul 4, 2025
EP4065119
Methods Of Treating Pulmonary Arterial HypertensionACTELION PHARMACEUTICALSJun 4, 2025
EP3801459
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSMay 6, 2025

Latest patents of Sandoz opposed by its competitors

Explore Sandoz's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3829682
Dec 4, 2024An Inhaler Device1
EP3373914
Jun 1, 2022Storage Stable Composition Comprising Rifaximin Alpha1
EP3536311
Dec 22, 2021Storage Stable Composition Comprising Rifaximin Alpha1
EP3434265
Jul 7, 2021Pharmaceutical Composition Containing Rifaximin Alpha & Delta3
EP3390358
Sep 23, 2020Crystalline Eravacycline Bis-Hydrochloride1
EP3416627
Apr 22, 2020Oral Dosage Form Comprising Rifaximin In Form Beta1
EP2785702
Jan 22, 2020Crystalline Dapagliflozin Hydrate1
EP2975050
May 29, 2019Quantification Of Misfolded Tnfr2:Fc1
EP2977372
May 8, 2019Polymorphs Of Febuxostat1
EP2988733
Mar 27, 2019Pharmaceutical Composition Containing Crystalline Macitentan1

Latest publications and patents of Sandoz New

Explore the latest publications and patents granted to Sandoz, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Sandoz

EP3829682
Dec 4, 2024An Inhaler DeviceGranted And Under Opposition
EP3373914
Jun 1, 2022Storage Stable Composition Comprising Rifaximin AlphaPatent Maintained As Amended
EP3536311
Dec 22, 2021Storage Stable Composition Comprising Rifaximin AlphaGranted And Under Opposition
EP3434265
Jul 7, 2021Pharmaceutical Composition Containing Rifaximin Alpha & DeltaRevoked
EP3390358
Sep 23, 2020Crystalline Eravacycline Bis-HydrochlorideGranted And Under Opposition
EP3416627
Apr 22, 2020Oral Dosage Form Comprising Rifaximin In Form BetaRevoked
EP2785702
Jan 22, 2020Crystalline Dapagliflozin HydrateOpposition Rejected
EP2975050
May 29, 2019Quantification Of Misfolded Tnfr2:FcRevoked
EP2977372
May 8, 2019Polymorphs Of FebuxostatRevoked
EP2988733
Mar 27, 2019Pharmaceutical Composition Containing Crystalline MacitentanRevoked

Latest PTAB cases involving Sandoz

Discover the latest PTAB cases involving Sandoz, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Sandoz

IPR2023-00478Feb 3, 2023SANDOZACERTA PHARMAInstitution Denied
PGR2022-00054Jul 29, 2022SANDOZBIOGEN MAInstitution Denied
PGR2022-00037May 2, 2022SANDOZBOEHRINGER INGELHEIMInstitution Denied
IPR2019-00865Mar 21, 2019SANDOZPHARMACYCLICSFinal Written Decision
IPR2018-00156Nov 6, 2017SANDOZABBVIE BIOTECHNOLOGYInstitution Denied
IPR2018-00002Oct 2, 2017SANDOZABBVIE BIOTECHNOLOGYInstitution Denied
IPR2017-02105Sep 14, 2017SANDOZABBVIE BIOTECHNOLOGYTerminated-Settled
IPR2017-02106Sep 14, 2017SANDOZABBVIE BIOTECHNOLOGYTerminated-Settled
IPR2017-02036Aug 31, 2017SANDOZGENENTECHInstitution Denied
IPR2017-02042Aug 31, 2017SANDOZGENENTECHInstitution Denied

Peer Comparison New

IP litigation analysis comparing Sandoz with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
SANDOZ1181619 -
ABBVIE BIOTECHNOLOGY - - - 22
BOEHRINGER INGELHEIM314221
NOVO NORDISK810519